NVCT
Nuvectis Pharma, Inc.Company Information
- Company Name
- Nuvectis Pharma, Inc.
- CIK
- CIK0001875558
- Category
- <br>Emerging growth company
- Ticker: Exchange
- NVCT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NVCT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-30
- Last sale
- 2024-11-07
- Shares purchased (TTM)
- 164,336
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 10,286,999
- Shares outstanding
- 23,475,989
- Ownership
- 43.82%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 18.06%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Assets Current | 22 | 25 | 32 | 36 | 27 | 30 | 19 | 17 | 18 | 20 | 19 | 22 | ||||||
| Cash And Cash Equivalents At Carrying Value | 22 | 25 | 32 | 35 | 27 | 30 | 19 | 17 | 18 | 19 | 19 | 22 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 22 | 25 | 32 | 36 | 27 | 30 | 19 | 17 | 18 | 20 | 19 | 22 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 5 | 5 | 6 | 6 | 5 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 13 | 11 | 13 | 12 | 10 | 9 | 9 | 6 | 6 | 6 | 7 | 6 | ||||||
| Employee Related Liabilities Current | 7 | 6 | 7 | 5 | 5 | 5 | 6 | 4 | 4 | 3 | 4 | 2 | ||||||
| Liabilities | 13 | 11 | 13 | 12 | 10 | 9 | 9 | 6 | 6 | 6 | 7 | 6 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 122 | 120 | 118 | 116 | 102 | 100 | 83 | 78 | 75 | 72 | 66 | 64 | ||||||
| Stockholders Equity | 9 | 14 | 18 | 24 | 17 | 21 | 10 | 11 | 13 | 14 | 12 | 17 | ||||||
| Retained Earnings Accumulated Deficit | -113 | -106 | -100 | -92 | -85 | -79 | -73 | -67 | -63 | -58 | -54 | -48 | ||||||
| Liabilities And Stockholders Equity | 22 | 25 | 32 | 36 | 27 | 30 | 19 | 17 | 18 | 20 | 19 | 22 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | ||||||
| Common Stock Shares Issued | 27 | 27 | 26 | 26 | 24 | 24 | 19 | 19 | 19 | 18 | 17 | 17 | ||||||
| Shares Outstanding | 27 | 27 | 26 | 26 | 24 | 24 | 19 | 19 | 19 | 18 | 17 | 17 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNuvectis Pharma, Inc. (NVCT) — SEC Financial Statements & Analysis
Nuvectis Pharma, Inc. (NVCT) is a pharmaceutical preparations company, incorporated in DE. Nuvectis Pharma, Inc. trades on Nasdaq as: NVCT. Nuvectis Pharma, Inc. (NVCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Nuvectis Pharma, Inc. carries a market cap of $431.72M, a P/E ratio of -14.26x, a P/B ratio of 47.54x, an enterprise value of $409.56M, and an EV/EBITDA multiple of -14.19x. On profitability, it posts a Return on Equity (ROE) of -233.30% and a Return on Assets (ROA) of -122.61%. Per share, it reports EPS of $-1.29, diluted EPS of $-1.29, free cash flow per share of $-0.83, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 37.20% year-over-year and EPS growth of 24.87% year-over-year. On the balance sheet, it maintains a current ratio of 1.68x, a quick ratio of 1.68x, working capital of $9.08M, a debt-to-equity ratio of 1.46x, a debt ratio of 0.59, free cash flow of $-19.51M (TTM), and net debt of $-22.16M. Figures sourced from SEC EDGAR.
- Market Cap
- $431.72M
- P/E TTM
- -14.26x
- EPS TTM
- $-1.29
- P/B TTM
- 47.54x
- ROE TTM
- -233.30%
- ROA TTM
- -122.61%
- Debt To Equity
- 1.46x
- Free Cash Flow TTM
- $-19.51M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Nuvectis Pharma, Inc. in?
Nuvectis Pharma, Inc. (NVCT) operates in the Pharmaceutical Preparations industry.
What exchange does NVCT trade on?
Nuvectis Pharma, Inc. (NVCT) trades on the Nasdaq.
Where is Nuvectis Pharma, Inc. incorporated?
Nuvectis Pharma, Inc. is incorporated in DE.
When was Nuvectis Pharma, Inc. (NVCT)'s most recent SEC filing?
Nuvectis Pharma, Inc. (NVCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is NVCT's market cap?
Nuvectis Pharma, Inc. (NVCT) has a market capitalization of $431.72M as of 2026-06-30.
What is NVCT's EPS (earnings per share)?
Nuvectis Pharma, Inc. (NVCT)'s trailing twelve month EPS is $-1.29 as of 2026-06-30.
What is NVCT's ROE (return on equity)?
Nuvectis Pharma, Inc. (NVCT)'s trailing twelve month Return on Equity (ROE) is -233.30% as of 2026-06-30.
What is NVCT's ROA (return on assets)?
Nuvectis Pharma, Inc. (NVCT)'s trailing twelve month Return on Assets (ROA) is -122.61% as of 2026-06-30.
What is NVCT's EV/EBITDA?
Nuvectis Pharma, Inc. (NVCT)'s trailing twelve month EV/EBITDA is -14.19x as of 2026-06-30.